Plasma Levels of Vascular Endothelial Growth Factor Before and After Intravitreal Injection of Aflibercept
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the plasma concentration of vascular endothelial
growth factor (VEGF) after standard treatment with one of the newest growth factor
inhibitors, aflibercept (Eylea).
Patients with exudative age-related macular degeneration (AMD) are treated today with
anti-growth factors (anti-VEGF). Eylea appears to have a longer duration of action in the eye
and a more powerful effect on the edema in the macula than previously used growth factor
inhibitors. This means that the disease can be controlled with fewer number of injections
into the eye and the investigators can therefore reduce the risk of complications associated
with this type of treatment.
It is unclear what the plasma VEGF concentration after treatment with Eylea into the eye in
patients with wet age-related macular degeneration is.